BMRN · Categories · Coverage
BMRN - Analyst coverage initiated
BioMarin Pharmaceutical Inc. (BMRN) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for BMRN
- BMO Capital Markets initiated coverage on BioMarin Pharmaceutical with a new price targetBMO Capital Markets initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $98.00
- Citigroup initiated coverage on BioMarin Pharmaceutical with a new price targetCitigroup initiated coverage of BioMarin Pharmaceutical with a rating of Buy and set a new price target of $75.00
- H.C. Wainwright initiated coverage on BioMarin Pharmaceutical with a new price targetH.C. Wainwright initiated coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $60.00
- Raymond James initiated coverage on BioMarin Pharmaceutical with a new price targetRaymond James initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $85.00
- Wolfe Research initiated coverage on BioMarin Pharmaceutical with a new price targetWolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00
- Evercore ISI initiated coverage on BioMarin Pharmaceutical with a new price targetEvercore ISI initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $113.00
- Wells Fargo initiated coverage on BioMarin Pharmaceutical with a new price targetWells Fargo initiated coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $100.00
- Raymond James initiated coverage on BioMarin PharmaceuticalRaymond James initiated coverage of BioMarin Pharmaceutical with a rating of Mkt Perform
- UBS initiated coverage on BioMarin Pharmaceutical with a new price targetUBS initiated coverage of BioMarin Pharmaceutical with a rating of Buy and set a new price target of $120.00
- Scotiabank initiated coverage on BioMarin Pharmaceutical with a new price targetScotiabank initiated coverage of BioMarin Pharmaceutical with a rating of Sector Perform and set a new price target of $95.00
- Bernstein initiated coverage on BioMarin Pharmaceutical with a new price targetBernstein initiated coverage of BioMarin Pharmaceutical with a rating of Underperform and set a new price target of $81.00
- Citigroup initiated coverage on BioMarin Pharmaceutical with a new price targetCitigroup initiated coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $116.00
- BMO Capital Markets initiated coverage on BioMarin Pharmaceutical with a new price targetBMO Capital Markets initiated coverage of BioMarin Pharmaceutical with a rating of Market Perform and set a new price target of $107.00
- Canaccord Genuity initiated coverage on BioMarin Pharmaceutical with a new price targetCanaccord Genuity initiated coverage of BioMarin Pharmaceutical with a rating of Hold and set a new price target of $119.00
- Cantor Fitzgerald initiated coverage on BioMarin Pharmaceutical with a new price targetCantor Fitzgerald initiated coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $110.00